In 269 children aged 1-10 with first steroid-sensitive nephrotic syndrome, mycophenolate mofetil was non-inferior to prednisone for treated relapse over 24 months (79.1% vs 74.8%), with less hypertension and psychological problems but more infections (69.9% vs 55.6%).
RCTn = 272
Benz et al. Mycophenolate mofetil versus prednisone for the initial treatment of idiopathic steroid-sensitive nephrotic syndrome in children in Germany (INTENT): a multicentre, open-label, randomised, controlled, parallel-group, non-inferiority, phase 3 trial